Eliminate-B
Precision BioSciences has developed PBGENE-HBV, the only therapy in clinical trials specifically designed to eliminate the root cause of chronic hepatitis B viral replication by targeting the cccDNA and integrated HBV.
ELIMINATE-B is a Phase 1, open-label, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B (ELIMINATE-B).
For more information or clinical trial inquiries please email our clinical team at:
ELIMINATE-B@precisionbiosciences.com